FrancophonIA/ELRC3.0 huggingface dataset:
English: Merck Sharp & Dohme BV, Postbus 581, 2003 PC, Haarlem The Netherlands
Estonian: Merck Sharp & Dohme BV, Postbus 581, 2003 PC, Haarlem
English: • One foil sachet filled with powder equal to 500 mg losartan potassium
Estonian: • üks pulbriga täidetud alumiiniumist fooliumkotike, mis sisaldab 500 mg losartaankaaliumi.
English: Place the cap on the bottle and shake the contents well to disperse.
Estonian: Asetage pudelile kork ja raputage hoolikalt pudelit, et lahus ja pulber seguneksid.
English: Respiratory, thoracic and mediastinal disorders: uncommon: dyspnoea
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired Aeg-ajalt: hingeldus.
English: Czech Republic Merck Sharp & Dohme BV, Postbus 581, Waarderweg 39,2003 PC, Haarlem, The Netherlands
Estonian: Merck Sharp & Dohme BV, Postbus 581, Waarderweg 39,2003 PC, Haarlem, Holland
English: Reconstitution of COZAAR oral suspension [for 200 ml of a 2.5 mg/ml suspension]:
Estonian: Cozaari suukaudse suspensiooni lahustamine (200 ml 2,5 mg/ml suspensiooni) Valage 240 ml läbipaistmatusse polüetüleenteraftalaat (PET) pudelisse 200 ml lahustit.
English: Czech Republic Merck Sharp & Dohme BV, Postbus 581, Waarderweg 39, 2003 PC, Haarlem, The Netherlands
Estonian: Merck Sharp & Dohme BV, Postbus 581, Waarderweg 39, 2003 PC, Haarlem, Holland
English: • Severe hepatic impairment.
Estonian: Teadmata: gripisarnased sümptomid.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION COZAAR and associated names (see Annex I) 2.5 mg/ml powder and solvent for oral suspension Losartan potassium.
Estonian: COZAAR ja sarnased nimetused (vt Lisa I) 2,5 mg/ml pulber ja lahusti suukaudse suspensiooni valmistamiseks.
English: The sachet should not be rinsed.
Estonian: Kotikest EI TOHI loputada.
English: Hepatobiliary disorders: rare: hepatitis not known: liver function abnormalities
Estonian: Maksa ja sapiteede häired Harv: hepatiit.
English: Respiratory, thoracic and mediastinal disorders: not known: cough
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired
English: Insert the syringe into the adaptor on the medicine bottle until a tight seal is made.
Estonian: Kinnitage süstal kindlalt ravimipudeli adapteri külge.
English: Cozaar 12,5 mg Inicio 12,5 mg Film-coated tabletOral use
Estonian: Cozaar 12,5 mg Inicio 12,5 mg
English: COZAAR 50 mg FILM-COATED TABLETS
Estonian: Cozaar 50 mg filmcoated tablets
English: Skin and subcutaneous tissue disorders:
Estonian: Lihas-skeleti ja sidekoe kahjustused
English: Nervous system disorders: Common: dizziness, vertigo
Estonian: Üldised häired ja manustamiskoha reaktsioonid Aeg-ajalt: asteenia, väsimus, tursed.
English: During administration of Losartan, removal of the angiotensin II negative feedback on renin secretion leads to increased plasma renin activity (PRA).
Estonian: Negatiivse tagasisidemehhanismi tõttu suureneb losartaani manustamise ajal reniini aktiivsus plasmas.
English: With the syringe, adapter, and bottle attached, turn the entire assembly upside down.
Estonian: Keerake süstal, adapter ja pudel üheskoos tagurpidi.
English: RP*>-1 (Relative potency by a mice potency test compared to a reference vaccine that was shown efficacious in sheep)
Estonian: RP* ≥ 1 (Suhteline potentsus hiire potentsustestiga võrrelduna referensvaktsiiniga, mis oli lammastel efektiivne)
English: Type I glass vials with chlorobutyl stopper and aluminium seal
Estonian: I tüüpi klaasviaalid klorobutüülkor gi ja alumiiniumkinn itusega
English: Further information on Extavia can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/extavia.
Estonian: Lisateave Extavia kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/extavia.
English: Extavia received a marketing authorisation valid throughout the EU on 20 May 2008.
Estonian: Extavia on saanud müügiloa, mis kehtib kogu ELis, 20. mail 2008.
English: What measures are being taken to ensure the safe and effective use of Extavia?
Estonian: Mis meetmed võetakse, et tagada Extavia ohutu ja efektiivne kasutamine?
English: What is Extavia and what is it used for?
Estonian: Mis on Extavia ja milleks seda kasutatakse?
English: Other information about Extavia
Estonian: Muu teave Extavia kohta
English: The European Medicines Agency decided that Extavia's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Extavia kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Why is Extavia authorised in the EU?
Estonian: Miks Extavia ELis heaks kiideti?
English: Extavia is used in patients:
Estonian: Extaviat kasutatakse järgmistel patsientidel:
English: As for all medicines, data on the use of Extavia are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Extavia kasutamise kohta pidevat järelevalvet.
English: This medicine is the same as Betaferon, which is already authorised in the EU.
Estonian: See ravim on samane ravimiga Betaferon, millel juba on ELis müügiluba.
English: Side effects reported with Extavia are carefully evaluated and any necessary action taken to protect patients.
Estonian: Extavia kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Extavia (interferon beta-1b)
Estonian: Extavia (beeta-1b-interferoon)
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Extavia have been included in the summary of product characteristics and the package leaflet.
Estonian: Extavia ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Extavia, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Extavia kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: • who have experienced the signs of MS for the first time, and these are severe enough to justify treatment with injected corticosteroids (anti-inflammatory medicines).
Estonian: • patsiendid, kellel tekkisid hulgiskleroosi sümptomid esimest korda ja on piisavalt rasked, et põhjendada ravi süstitavate kortikosteroididega (teatud põletikuvastased ravimid).
English: In both studies, Extavia showed a reduction in the number (30%) of clinical relapses.
Estonian: Mõlemas uuringus vähendas Extavia kliiniliste relapside arvu (30%).
English: In the second study, no delay in the time to disability progression was seen.
Estonian: Teises uuringus ei täheldatud puude süvenemiseni kulunud aja pikenemist.
English: The most frequent side effects with Extavia are flu-like symptoms (including fever, chills, joint pain, malaise [feeling unwell], sweating, headache and muscle pain) and reactions at the site of injection.
Estonian: Extavia kõige sagedamad kõrvalnähud on gripilaadsed sümptomid (sh palavik, külmavärinad, liigesevalu, halb enesetunne, higistamine, peavalu ja lihasevalu) ning süstekoha reaktsioonid.
English: What are the risks associated with Extavia?
Estonian: Mis riskid Extaviaga kaasnevad?
English: Extavia must not be used in patients who have decompensated liver disease (when the liver is damaged and can no longer work adequately).
Estonian: Extaviat ei tohi kasutada patsiendid, kellel on dekompenseeritud maksahaigus (olukord, kus maks on kahjustunud ega toimi enam normaalselt).
English: One of the two studies showed a significant delay in the time to disability progression (31% risk reduction due to Extavia) and in the time to becoming wheelchair bound (39%).
Estonian: Üks uuringutest tõendas, et aeg puude süvenemiseni (Extavia tõttu vähenes risk 31%) ja ratastooli jäämiseni (39%) pikenes oluliselt.
English: Extavia must not be used in patients who have severe depression or have thoughts of suicide.
Estonian: Extaviat ei tohi kasutada raske depressiooni või suitsiidimõtetega patsiendid.
English: • who have MS of the type known as ‘relapsing-remitting', when the patient has attacks (relapses) between periods with no symptoms (remissions), and with at least two relapses within the last two years;
Estonian: • patsiendid, kellel on hulgiskleroosi relapseeruv-remiteeruv vorm, kui patsiendil esinevatele relapsidele ehk haiguse ägenemistele järgnevad remissioonid ehk sümptomiteta perioodid ning kui kahel viimasel aastal esines vähemalt kaks relapsi;
English: Extavia was more effective than placebo in reducing the number of annual relapses: patients receiving the medicine had on average 0.84 relapses a year, when patients on placebo had 1.27 relapses.
Estonian: Extavia oli aastase relapside arvu vähendamisel efektiivsem kui platseebo: ravimit saanud patsientidel tekkis aastas keskmiselt 0,84 relapsi ja platseebot saanud patsientidel 1,27 relapsi.
English: Extavia is available as a powder and solvent that are made up into a solution that supplies a dose of 250 micrograms.
Estonian: Extaviat turustatakse pulbri ja lahustina, millest valmistatakse lahus, mis sisaldab 250 µg annust.
English: The exact way that Extavia works in MS is not yet known but the active substance, interferon beta-1b, seems to calm down the immune system, and prevents relapses of MS.
Estonian: Extavia täpne toimemehhanism hulgiskleroosi korral ei ole veel teada, kuid selle toimeaine beeta-1b-interferoon näib vähendavat immuunsüsteemi aktiivsust, hoides ära hulgiskleroosi relapside teket.
English: For the full list of side effects and restrictions with Extavia, see the package leaflet.
Estonian: Extavia kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them.
Estonian: Hulgiskleroosi korral on immuunsüsteemi (organismi looduslike kaitsemehhanismide) toimimine häiritud ja see ründab närvisüsteemi osi (peaaju, seljaaju ja nägemisnärvi (närv, mis edastab silmast signaale peaajju)), põhjustades põletikku, mis kahjustab närve ja neid ümbritsevat kesta.
English: The company that makes Betaferon has agreed that its scientific data can be used for Extavia.
Estonian: Betaferoni tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Extavia toetuseks (teabel põhinev nõusolek).
English: Extavia can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of MS.
Estonian: Extavia on retseptiravim ja ravi peab alustama hulgiskleroosi ravis kogenud arst.
English: In a study involving 487 patients with a single demyelinating event, treatment with Extavia for two years was shown to reduce the risk of developing clinically defined MS: 28% of the patients who received Extavia developed MS, compared with 45% of those who received placebo.
Estonian: Uuringus, mille osales 487 ühe demüeliniseerumisepisoodiga patsienti, tõendati, et 2-aastane ravi Extaviaga vähendas kliiniliselt määratletud hulgiskleroosi tekke riski: hulgiskleroos tekkis 28%-l Extaviat saanud patsientidest ja 45%-l platseebot saanutest.
English: Extavia contains the active substance interferon beta-1b.
Estonian: Extavia sisaldab toimeainena beeta-1b-interferooni.
English: The active substance in Extavia is the protein interferon beta-1b, one of a group of interferons that can be naturally produced by the body to help it fight against viruses and other attacks.
Estonian: Extavia toimeaine on looduslike interferoonide rühma kuuluv valk beeta-1b-interferoon, mis tekib organismis, et aidata sel võidelda viiruste ja muude haigustekitajatega.
English: What benefits of Extavia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Extavia kasulikkus?
English: Extavia is a medicine used to treat adults who have multiple sclerosis (MS).
Estonian: Extavia on ravim, mida kasutatakse multiipel- ehk hulgiskleroosiga täiskasvanute raviks.
English: Extavia was studied over a two-year period in 338 patients with relapsing remitting MS who were able to walk unaided, where its effectiveness was compared with placebo (a dummy treatment).
Estonian: Extaviat uuriti kahe aasta jooksul 338 relapseeruva-remiteeruva hulgiskleroosiga patsiendil, kes suutsid kõndida kõrvalise abita, ning ravimi efektiivsust võrreldi platseeboga (näiv ravim).
English: It is used when the patient is considered to be at high risk of developing MS. Before using Extavia, doctors need to exclude other causes for the symptoms;
Estonian: Enne Extavia kasutamist peab arst välistama muud sümptomite põhjused;
English: Extavia has also been studied in 1,657 patients in two studies involving secondary progressive MS patients who were able to walk, where it was compared with placebo.
Estonian: Extaviat võrreldi platseeboga ka 1657 patsiendil kahes uuringus, milles osalesid sekundaarse progressiivse hulgiskleroosiga kõndimisvõimelised patsiendid.
English: The patients can inject Extavia themselves once they have been trained.
Estonian: Pärast asjakohase väljaõppe saamist tohivad patsiendid süstida endale Extaviat ise.
English: How is Extavia used?
Estonian: Kuidas Extaviat kasutatakse?
English: An overview of Extavia and why it is authorised in the EU
Estonian: Ülevaade ravimist Extavia ja ELis müügiloa väljastamise põhjendus
English: How does Extavia work?
Estonian: Kuidas Extavia toimib?
English: Extavia treatment should be stopped in patients whose condition does not improve.
Estonian: Kui patsiendi seisund ei parane, tuleb ravi Extaviaga lõpetada.
English: What measures are being taken to ensure the safe and effective use of Ilaris?
Estonian: Mis meetmed võetakse, et tagada Ilarise ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Ilaris on 23 October 2009.
Estonian: Euroopa Komisjon andis Ilarise müügiloa, mis kehtib kogu Euroopa Liidus, 23. oktoobril 2009.
English: The full EPAR for Ilaris can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ilarise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: − familial mediterranean fever (FMF);
Estonian: − perekondlik Vahemere palavik (FMF);
English: Periodic fever syndromes
Estonian: Perioodilise palaviku sündroomid
English: What is Ilaris and what is it used for?
Estonian: Mis on Ilaris ja milleks seda kasutatakse?
English: Other information about Ilaris
Estonian: Muu teave Ilarise kohta
English: The proportion of patients with no relapse was lower (around 57%) for children aged 2 to 4 years.
Estonian: Relapsideta patsientide osakaal oli väiksem (ligikaudu 57%) 2-4-aastastel lastel.
English: Ilaris was originally authorised under ‘exceptional circumstances', because, for scientific reasons, limited information was available at the time of approval.
Estonian: Ilaris kiideti esialgu heaks erandkorras, sest teaduslikel põhjustel ei olnud heakskiitmise ajal võimalik saada Ilarise kohta täielikku teavet.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 22 March 2017
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandkorras väljastatus 22. Märtsil 2017.
English: Why is Ilaris approved?
Estonian: Miks Ilaris heaks kiideti?
English: Some infections were unusual or opportunistic infections due to reduced white blood cell levels.
Estonian: Teatud infektsioonid olid vere valgeliblede vähese sisalduse tõttu ebaharilikud või oportunistlikud.
English: Ilaris must not be used in patients with active or severe infection.
Estonian: Ravimit ei tohi kasutada aktiivse või ägeda infektsiooniga patsiendid.
English: − hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD);
Estonian: − hüperimmunoglobuliin-D-sündroom (HIDS) / mevalonaadi kinaasi vaegus (MKD);
English: Ilaris treatment also allowed patients to reduce the amount of steroids they take to control inflammation.
Estonian: Ravi Ilarisega võimaldas patsientidel ka vähendada steroidide hulka, mida nad võtsid põletiku kontrollimiseks.
English: After proper training, patients or their caregivers may inject Ilaris themselves if the doctor deems it appropriate (for gouty arthritis the medicine should always be given by a healthcare professional).
Estonian: Patsiendid või nende hooldajad tohivad pärast asjakohase väljaõppe saamist süstida Ilarist ise, kui arst peab seda asjakohaseks (podagraartriidi korral tohib ravimit manustada ainult tervishoiutöötaja).
English: The main risk with this medicine is infection, mostly affecting the nose and throat.
Estonian: Ravimi põhirisk on infektsioon, enamasti nina- ja kurguinfektsioon.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits seen with Ilaris outweigh its risks and recommended that it be authorised in the EU.
Estonian: Inimravimite komitee otsustas, et Ilarise kasulikkus on suurem kui sellega kaasnevad riskid ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: It is not intended to provide practical advice on how to use Ilaris.
Estonian: Hindamisaruandes ei anta Ilarise kasutamise praktilisi nõuandeid.
English: Gouty arthritis
Estonian: Podagraartriit
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ilaris have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ilarise ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Ilaris is a medicine for treating the following inflammatory conditions:
Estonian: Ilaris on ravim, mida kasutatakse järgmiste põletikuseisundite raviks:
English: What are the risks associated with Ilaris?
Estonian: Mis riskid Ilarisega kaasnevad?
English: In patients taking Ilaris, after 3 days, the pain level was reduced from 74 to 25 (on a standard rating scale from 0 to 100), whereas in patients taking the comparator the pain level was reduced from 74 to 35.
Estonian: Ilarist manustanud patsientidel vähenes valu 3 päeva pärast manustamist 74-lt 25-le (hindamise standardskaalal 0-100), võrdlusravimit manustanud patsientidel vähenes valu 74-lt 35-le.
English: By attaching to interleukin-1 beta, canakinumab blocks its activity, helping to reduce inflammation thereby relieving the symptoms of the diseases.
Estonian: Virgatsainega interleukiin-1β seondumisel blokeerib kanakinumaab aine toime ja aitab leevendada haiguse sümptomeid.
English: − cryopyrin-associated periodic syndromes (CAPS);
Estonian: − krüopüriiniga seotud perioodilised sündroomid (CAPS);
English: • 4 types of periodic fever syndromes (diseases marked by recurring inflammation and fever) in adults and children aged 2 and above:
Estonian: • 4 tüüpi perioodilise palaviku sündroomid (korduva põletiku ja palavikuga haigused) täiskasvanutel ja vähemalt 2-aastastel lastel;
English: This is a summary of the European public assessment report (EPAR) for Ilaris.
Estonian: See on ravimi Ilaris Euroopa avaliku hindamisaruande kokkuvõte.
English: The company that markets Ilaris will provide doctors who will use Ilaris with educational material containing the prescribing information, the patient reminder card and information for doctors containing important safety information about Ilaris, including precautions to be taken when using the medicine.
Estonian: Ilarise turustaja edastab arstidele, kes hakkavad Ilarist kasutama, teabepakme, mis sisaldab ravimi määramise teavet, patsiendi hoiatuskaarti ning arstidele suunatud olulist teavet ravimi ohutuse ja nõuetekohase kasutamise kohta, sealhulgas ettevaatusmeetmeid.
English: What benefits of Ilaris have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ilarise kasulikkus?
English: Three studies involving 220 adults and children 2 years and older showed that Illaris was effective at reducing relapses of CAPS symptoms after a 24-week treatment period.
Estonian: Kolm uuringut, milles osales 220 täiskasvanut ja vähemalt 2-aastast last, tõendasid, et Ilaris on efektiivne krüopüriiniga seotud perioodiliste sündroomide relapside arvu vähendamisel pärast 24nädalast raviperioodi.
English: The risk of developing a new gouty arthritis attack was also reduced with Ilaris (17% with Ilaris versus 37% with triamcinolone acetonide).
Estonian: Ilaris vähendas ka uue podagraartriidi episoodi tõenäosust (17% Ilarise ja 37% triamtsinoloonatsetoniidi kasutamisel).
English: Serious infections have been observed in patients taking Ilaris.
Estonian: Ilarist võtvatel patsientidel on täheldatud raskeid infektsioone.
English: For practical information about using Ilaris, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Ilarise kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: How is Ilaris used?
Estonian: Kuidas Ilarist kasutatakse?
English: How does Ilaris work?
Estonian: Kuidas Ilaris toimib?
English: The most common infections were of the nose and throat.
Estonian: Kõige sagedamad olid nina- ja kurguinfektsioonid.
English: In a second study in childhood Still's disease (177 patients), the risk of experiencing a disease flare was reduced by 64% with Ilaris, compared with placebo.
Estonian: Teises uuringus, milles osales 177 lapseea Stilli tõvega patsienti, oli Ilarise kasutamisel haiguse ägenemise risk 64% väiksem kui platseebo korral.
English: Studies have shown that Ilaris is effective at reducing symptoms or relapses in patients with periodic fever syndromes, Still's disease and gouty arthritis.
Estonian: Uuringud tõendasid Ilarise efektiivsust sümptomite ja relapside vähendamisel perioodilise palaviku sündroomide, Stilli tõve ja podagraartriidiga patsientidel.
English: The response rates with Ilaris and placebo were 46% and 8%, respectively in patients with TRAPS, 35% and 6% in patients with HIDS/MKD, and 61% and 6% in patients with FMF.
Estonian: Ilarise ja platseeboga saadud ravivastused olid kasvaja nekroositeguri retseptoriga seotud perioodilise sündroomi korral vastavalt 46% ja 8%, hüperimmunoglobuliin-D-sündroomi / mevalonaadi kinaasi vaeguse korral vastavalt 35% ja 6% ning perekondliku Vahemere palaviku korral vastavalt 61% ja
English: Because of the similarities between childhood Still's disease and the adult form (adult-onset Still's disease, AOSD), Ilaris is expected to have similar benefits in adults.
Estonian: Et lapseea Stilli tõbi ja Stilli tõve täiskasvanutel esinev vorm (täiskasvanute Stilli tõve episoodid) on sarnased, eeldatakse, et Ilaris toimib täiskasvanutel sarnaselt lastega.
English: For the full list of all side effects reported with Ilaris, see the package leaflet.
Estonian: Ilarise kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Injections are usually given in the upper thigh, upper arm, abdomen or buttocks.
Estonian: Süstid tehakse tavaliselt reie ülaossa, õlavarde, kõhupiirkonda või tuharasse.
English: Two studies involving 454 patients with gouty arthritis showed that Ilaris was more effective than another anti-inflammatory medicine triamcinolone acetonide at reducing pain.
Estonian: Kaks uuringut, milles osales 454 podagraartriidiga patsienti, tõendasid, et Ilaris oli valu leevendamisel efektiivsem kui teine põletikuvastane ravim triamtsinoloonatsetoniit.
English: The active substance in Ilaris, canakinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a messenger molecule or ‘cytokine' in the body called interleukin-1 beta.
Estonian: Ilarise toimeaine kanakinumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva virgatsaine tsütokiini (interleukiin-1β) ja seondub sellega.